Eyelid skin involvement in pemphigus foliaceus

Ocular Immunology and Inflammation

Volumn 13, Issue 5, 2005, Pages 389-394

  Daoud, Yassine J ^a   Foster, C Stephen ^a   Ahmed, A Razzaque ^b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^c NEW ENGLAND BAPTIST HOSPITAL   (United States)

Author keywords

Desmoglein 1; Eyelids; Intravenous immunoglobulin (IVIg) therapy; Pemphigus foliaceus

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; DAPSONE; IMMUNOGLOBULIN G; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; EYELID BIOPSY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; MALE; PEMPHIGUS FOLIACEUS; VISUAL ACUITY;

ADULT; ANTIBODIES, ANTI-IDIOTYPIC; BIOPSY; DESMOGLEIN 1; DESMOGLEIN 3; DIAGNOSIS, DIFFERENTIAL; EYELID DISEASES; EYELIDS; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; FOLLOW-UP STUDIES; HUMANS; IMMUNOBLOTTING; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MALE; MICROSCOPY, CONFOCAL; PEMPHIGUS; RETROSPECTIVE STUDIES;

EID: 28244450270     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.1080/09273940590951025     Document Type: Article

References (14)

1. Diaz LA, Sampaio SA, Rivitti EA, Martins CR, Cunha PR, Lombardi C, Almeida FA, Castro RM, Macca ML, Lavrado C, et al. Endemic pemphigus foliaceus (fogo selvagem). I. Clinical features and immunopathology. J Am Acad Dermatol. 1989;20:657-669.
2. Emery DJ, Diaz LA, Fairley JA, Lopez A, Taylor AF, Giudice GJ. Pemphigus foliaceus and pemphigus vulgaris autoantibodies react with the extracellular domain of desmoglein-1. J Invest Dermatol. 1995;104:323-328.
3. Adams MJ, Reichel MB, King IA, Marsden MD, Greenwood MD, Thirlwell H, Arnemann J, Buxton RS, Ali RR. Characterization of the regulatory regions in the human desmoglein genes encoding the pemphigus foliaceous and pemphigus vulgaris antigens. Biochem J. 1998;329:165-174.
4. Ioannides D, Hytiroglou P, Phelps RG, Bystryn JC. Regional variation in the expression of pemphigus foliaceus, pemphigus erythematosus, and pemphigus vulgaris antigens in human skin. J Invest Dermatol. 1991;96:159-161.
5. Ahmed AR, Dahl MV. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol. 2003;139:1051-1159.
6. Kishibe M, Kinouchi M, Ishida-Yamamoto A, Koike K, Iizuka H. Pemphigus foliaceus localized to the nose. Clin Exp Dermatol. 2003;28:560-562.
7. Newton JA, McGibbon DH, Monk B, Rowell NR. Pemphigus foliaceus localized to the nose. Br J Dermatol. 1988;118:303-305.
8. Ahmed AR, Sami N. Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional therapy. J Am Acad Dermatol. 2002;46:42-49.
9. Ahmed AR. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol. 2001;45:825-835.
10. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001;345:747-755.
11. Sami N, Bhol KC, Ahmed AR. Influence of IVIg therapy on autoantibody titers to desmoglein 1 in patients with pemphigus foliaceus. Clin Immunol. 2002;105:192-198.
12. Ahmed AR. Treatment of autoimmune mucocutaneous blistering diseases with intravenous immunoglobulin therapy. Exp Opin Invest Drugs. 2004;13:1019-1032.
13. Shirakata Y, Amagai M, Hanakawa Y, Nishikawa T, Hashimoto K. Lack of mucosal involvement in pemphigus foliaceus may be due to low expression of desmoglein 1. J Invest Dermatol. 1998;110:76-78.
14. Amagai M, Koch PJ, Nishikawa T, Stanley JR. Pemphigus vulgaris antigen (desmoglein 3) is localized in the lower epidermis, the site of blister formation in patients. J Invest Dermatol. 1996;106:351-355.